Intangible Assets

BJDX does not show evidence of durable brand, proprietary IP, or regulatory exclusivity in the provided filings-based inputs, so it lacks the kind of protected asset base that would sustain pricing power versus peers.

The absence of disclosed long-run margin or ROIC history in the supplied metrics suggests no demonstrated intangible-led advantage, while stronger peers in regulated or IP-heavy healthcare niches typically show clearer persistence.

Without identifiable patents, trademarks, or clinical-data exclusivity that directly translate into retention or premium pricing, any intangible advantage appears replicable rather than structurally durable.

Switching Costs

The provided metrics do not indicate meaningful customer lock-in, and the deeply negative TTM ROIC implies BJDX is not monetizing a sticky installed base better than peers.

No evidence is provided of workflow integration, reimbursement dependence, or contract structures that would make customers materially costly to replace, unlike stronger healthcare service or software peers.

Because retention and pricing power are not evidenced in the supplied data, switching costs appear limited and insufficient to support a durable moat over a 5–10 year horizon.

Network Effects

BJDX shows no visible network-effect mechanism in the supplied information, so customer value does not appear to rise materially as usage expands.

Unlike platform peers where more users, data, or counterparties reinforce adoption, the available metrics do not show any self-reinforcing ecosystem that would compound advantage.

In the absence of evidence that peers or customers depend on BJDX for core functionality, network effects are effectively not a source of moat.

Cost Advantage

The negative ROIC and ROCE indicate BJDX is not operating with a cost structure that converts scale into superior returns versus peers.

No evidence is provided of lower unit costs, superior asset productivity, or procurement leverage that would create a persistent cost edge.

Because the company is not demonstrating durable margin or capital efficiency advantages, cost advantage does not appear to be a meaningful moat driver.

Efficient Scale

The supplied data do not indicate that BJDX serves a niche market with natural monopoly characteristics or that industry demand is too small for multiple efficient competitors.

Unlike peers in highly concentrated infrastructure or regulated markets, there is no evidence that BJDX benefits from a structurally limited market that protects returns.

Without proof of exclusive access to a constrained market or a scale threshold that deters entry, efficient scale is weak and not clearly superior to peers.

Overall Score

BJDX appears to have a weak and non-durable moat versus peers because the provided evidence does not show protected intangibles, meaningful switching costs, network effects, cost advantage, or efficient scale, and the negative TTM ROIC/ROCE further suggests limited pricing power and poor structural retention of value.